Overview

A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

Status:
Not yet recruiting

Trial end date:
2032-12-31

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the long-term safety of apremilast in participants 2 years of age or older with oral ulcers associated with Behçets disease or 5 years of age or older with active juvenile psoriatic arthritis that have completed Study 20190530 or Study 20190529.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Apremilast